The Innovations Dr. David Samadi Has Brought to Prostate Surgery

At Lenox Hill Hospital, Dr. David Samadi is Chairman of Urology and Chief of Robotic Surgery and has performed over 7000 robotic prostate surgeries using the DaVinci System along with the SMART(Samadi Modified Advanced Robotic Technique) surgery technique developed by Dr. Samadi which allows for much smaller incisions as well as shorter surgical times that leads to faster recovery times.

In an interview Dr. David Samadi described how he was inspired by a former CEO of JetBlue explaining how their crews quickly clean out planes and make them ready for the next flight. He developed surgical crew techniques that allow him to perform his next surgery within ten minutes of the last one by having his crew start cleaning up a half hour before the surgery is through.

Born in the Persian Jewish community in Iran, at 15 years of age Dr. David Samadi and his brother Dan, then just 12, were forced to leave after the Revolution in 1979 and were sent to Belgium and then moved to London after 6 months and in 1984 moved to America. Dr. Samadi attended the State University of New York at Stony Brook where he received a degree in biochemistry and then a master’s degree from the Stony Brook School of Medicine. He did his postgraduate training at Montefiore Medical Center in Urology and completed his training at Albert Einstein College of Medicine and Montefiore Medical Center.

Dr. Samadi has a website called Dr. David Samadi TV where he livestreams new episodes every Sunday at 12:30 PM. The website offers videos on various medical subjects and of course many discussing prostate cancer, including screening, treatments and what to expect after surgery.

On social media he offers much the same content as Dr. David Samadi TV where he discusses a variety of medical topics including, the importance of exercise and healthy eating as well as posts discussing various medical issues from hypertension to shingles but also many about prostate cancer.

Earlier this year, Dr. Samadi wrote an article for the Huffington Post describing a good prognosis for Mitt Romney after successful prostate surgery for a slow growing tumor found in 2017.

Dr. Samadi has been the recipient of The Patients’ Choice Award as well as the Most Compassionate Doctor and the American Cancer Society’s Partner Award. New York Magazine named him Best Doctor in 2009, 2010, 2011, 2012 and 2015.

Dr. David Samadi’s Facebook Page: www.facebook.com/DrDavidSamadi/

Cancer Treatment Centers of America Helps People Learn The Statistics

Among the things people need to know about cancer is the statistics of each cancer. After all, different forms of cancer have different rates of survival. This is one of the reasons that Cancer Treatment Centers of America are willing to provide this type of information. After all, people who have knowledge have more of the tools needed to move forward with the needed treatment. This is one thing that is going to make the difference in the lives of the patient that is suffering from cancer. The only thing is that the patient has to be willing to take the necessary steps to treat the cancer and at least reduce the damages that it does.

Cancer Treatment Centers of America is one of the facilities that are going to equip people with the tools that they need to be prepared for if they detect cancer in their bodies. Among the things they will have listed is information on each cancer including the symptoms that come with it. They will also provide people with what it is going to take to effectively treat it and the side effects of the treatment. With the right type of preparation, the patient is going to be able to get through the cancer and come out stronger. Visit https://www.myctca.com/ to know more about CTCA.

When it comes to cancer, knowledge is power. It is very important for even people who do not have cancer to learn everything they can about the cancer disease. After all, there is no telling whether or not they are going to have cancer or when they are going to get it. Also, one can’t predict at what stage it is going to be in before it is detected in the person. Fortunately, the individual has access to a lot of the effective treatments that they could use for their recovery.

For more information follow CTCA on Twitter.

Rutgers Cancer Institute Launches the Omar Boraie Chair in Genomic Science

The newly established Omar Boraie Chair in Genome Science at Rutgers Cancer Institute of New Jersey will help to propel groundbreaking research in precision medicine, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute. Endowed chairs are considered gold standards in higher education because they express the commitment that universities have put on growing academic disciplines at the highest levels, and ensure their continued support.

The Rutgers Cancer Institute chair is named for philanthropic New Brunswick real estate developer, Omar Boraie. The developer has pledged to donate $1.5 million to support it. The Omar Boraie Chair is part of the “18 Chair Challenge,” a campaign by Rutgers University. In the campaign, an anonymous donor provides $1.5 million to match each of the 18 new chairs. The result is a total endowment of $3million. Rutgers Cancer Institute of New Jersey is a comprehensive cancer center with a national status.

Evolving Precision Medicine

Precision medicine and genomic science fields are changing the approach of medical doctors towards the diagnosis of cancer and its treatment. The relatively new field involves genetic-level treatment and analysis of cancerous tumors, which allows oncologists to prescribe individualized therapies correctly. The importance of precision medicine was attested during the recent state of the Union Address by President Barrack Obama. In the speech, the president proclaimed the launch of a nationwide precision medicine initiative.

Although presently several cancer research centers are performing next-generation gene sequencing, the Rutgers Cancer Institute was a national pioneer in the field. Genomic sequencing has been instrumental in coming up with novel therapies that help people with poor prognoses, rare cancers, and those with limited treatment options. Precision medicine advancements have allowed the classification of cancers into subpopulations sharing similar characteristics although they have different genetic make-up.

Omar Boraie said that he was happy with the work done at Rutgers Cancer Institute because it has made advances in precision medicine, especially for non-responsive patients. He wondered how awesome it would be if the science were applied to everybody suffering from cancer. He concluded by saying that he was hopeful that his family’s $1.5 million pledge would inspire other well-wishers to come out and support the cause.

Rutgers Institutes’ Director, Robert S. DiPaola, MD, said that the entire institute was grateful to Boraie’s generosity and support. He added that Boraie was an integral part of New Brunswick’s development as a “Healthcare City.” Shridar Ganesan, a principal investigator at the Rutgers Institute, was named to the Omar Boraie Chair. He is a medical oncologist who is also internationally renowned as a top academic leader and researcher.

An innovative Way to Treat Cancer with Clay Siegall at Seattle Genetics

With an innovative scientific method and research capabilities behind creating an antibody-drug conjugate, Seattle Genetics has proved itself to be an innovative company that is truly dedicated to helping individuals around the world have a new method for killing cancer without putting toxins in the body. Seattle Genetics was founded in 1998 by Clay Siegall, a leader in the science community who has had years of professional experience with development and research. As the President as well as the CEO of this company, Clay Siegall co-founded this company in order to offer individuals a new therapeutic method to treating cancer. This biotechnology company not only specializes in developing innovative scientific discoveries, but also specializes in commercializing each product that is made to the public. As a company that is currently the leader of an antibody-drug conjugate, Dr. Clay Siegall and his employees have received awards and recognition for their excellent work and research within the industry of science.

The antibody-drug conjugate is a treatment for cancer without the harmful effects that can come from radiation or even from chemotherapy. As an ADC, this conjugate is designed to target monoclonal antibodies. In doing this, the ADC delivers cell-killing agents that are designed to target the cancer cells without harming other cells within the body. This innovation leads to a healthier outcome within the body. The use of ACDs has been approved in over 60 countries and has helped millions of individuals with cancer. In collaboration with Takeda Pharmaceutical Company Limited, the two have continuously negotiated with other countries in order to spread this treatment to other countries in need of a cheap solution.

Above all, the main goal of this company is to help people who have suffered from cancer. With a corporate culture, this company has successfully valued integrity, scientific excellence, innovation, and even team work. As the acknowledged leader of the antibody-drug conjugate, this company hopes to expand more into the future. Clay Siegall states that the reason behind his decision to create this product is to offer a new and non-toxic way to treat cancer without ever having to break the bank.

Learn More:

https://twitter.com/seattlegenetics

http://people.equilar.com/bio/clay-siegall-seattle-genetics/salary/42318#.V3_Y2Y6RKGg

The New ADC Treatment by Seattle Genetics

For anyone who has had cancer or who has experienced a loved one suffer or die from the disease, they understand how the condition affects the patient and leaves them in a bad state. Treating cancer is not an easy thing to do. Medical researchers have made strides in finding a cure for cancer but there is still a long way to go in terms of finding lasting treatment solutions.

While there are many researches underway, there are however, many innovations in the biotechnology field. One of them is the recent treatment option by Seattle Genetics a biotechnology company located in the United States. The company has come up with a treatment technology known as ADC. ADC, which stands for Anti-body drug conjugate, is a technology which uses agents to kill cancer cells in the body.

The concept behind the treatment by ADC technology is that the patient is not subjected to the horror that comes with chemotherapy. They are able to recover faster since the therapy does not harm the normal and unaffected cells. The agents only kill the cancer cells living the normal ones to thrive. The treatment is one of the best methods of slowing the effects of cancer and ensuring that patients recover faster.

  1. Clay Siegall is the CEO and founder of Seattle Genetics. He is the brain behind the company and he has done a lot to ensure that the company provides the best innovative technologies in the field of biomedicine. What most people do not know about Mr. Siegall is that apart from being the founder of Seattle Genetics, he is also a researcher. He is a scientist whose area of specialty is therapies. He is also an enthusiast of drug research and treatments.

AT Seattle Genetics, there is a team of experts who work around the clock to make sure that they come up with therapies and treatment technologies for many diseases. They have a passion for those suffering from various medical conditions including cancer. With their dedication and expertise, they have helped patients get efficient and effective treatment for cancer.

Learn more:
http://www.seattlegenetics.com/clay_siegall

http://seekingalpha.com/article/3969434-seattle-genetics-sgen-clay-b-siegall-q1-2016-results-earnings-call-transcript